Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

69.29
Delayed Data
As of 4:15pm ET
 -0.56 / -0.80%
Today’s Change
65.38
Today|||52-Week Range
103.10
-3.24%
Year-to-Date
Sarepta Leads Biotech Movers on Voucher Deal News
10:18am / TheStreet.com - Paid Partner Content
Consider Gilead Sciences
Feb 14 / GuruFocus News - Paid Partner Content
Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead
10:16am / Zacks.com - Paid Partner Content
No Bottoming Signs Yet for Gilead
Feb 14 / TheStreet.com - Paid Partner Content
Big pharma bets billions on 'silent' liver disease
12:08am / FT.com - Paid Partner Content
Curing Disease Is Bad For Business: How Do Big Pharma Companies Continue Their Growth...
Feb 14 / Benzinga - Paid Partner Content
Your Burning Biotech Questions Answered
Feb 20 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exeli...
Feb 14 / Zacks.com - Paid Partner Content
Why Gilead Sciences Is a Buy
Feb 19 / MotleyFool.com - Paid Partner Content
Why I Just Bought More Shares of Gilead Sciences, Inc.
Feb 14 / MotleyFool.com - Paid Partner Content
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Feb 18 / MotleyFool.com - Paid Partner Content
GSK claims new HIV combination therapy will be 'less harmful'
Feb 13 / FT.com - Paid Partner Content
Five Major Myths about Options Trading
Feb 17 / Zacks.com - Paid Partner Content
Better Buy: Illumina or Gilead Sciences?
Feb 13 / MotleyFool.com - Paid Partner Content
Why President Trump Should Buy Gilead Sciences
Feb 17 / MotleyFool.com - Paid Partner Content
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
Feb 13 / Zacks.com - Paid Partner Content
Your Burning Biotech Questions Answered
Feb 17 / TheStreet.com - Paid Partner Content
Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb 13 / Zacks.com - Paid Partner Content
Thanks, Martin Shkreli, for the Dumbest Advice Ever on Drug Pricing
Feb 17 / MotleyFool.com - Paid Partner Content
Why Intercept Pharmaceuticals' Latest News Caused the Stock to Jump
Feb 11 / MotleyFool.com - Paid Partner Content
Investors Are Betting Big Against Intercept Pharmaceuticals. Are They Wrong?
Feb 17 / MotleyFool.com - Paid Partner Content
Biotech ETFs Powered by Q4 Earnings
Feb 10 / Zacks.com - Paid Partner Content
North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Communi...
Feb 16 / GuruFocus News - Paid Partner Content
Don't Panic: Gilead Sciences Really Isn't a Value Trap
Feb 09 / MotleyFool.com - Paid Partner Content
10 Undervalued Stocks for the Enterprising Investor
Feb 16 / GuruFocus News - Paid Partner Content
Stock Market News for February 09, 2017
Feb 09 / Zacks.com - Paid Partner Content
D. E. Shaw & Co., Inc. Buys Netflix, NXP Semiconductors NV, Medtronic PLC, Sells Amaz...
Feb 16 / GuruFocus News - Paid Partner Content
Why Gilead Sciences, Zillow Group, and Parsley Energy Slumped Today
Feb 08 / MotleyFool.com - Paid Partner Content
Under the Microscope: Gilead's Recent Dividend Increase
Feb 15 / GuruFocus News - Paid Partner Content
5 Things Gilead Sciences' Management Said as Its Stock Slumped
Feb 08 / MotleyFool.com - Paid Partner Content
Movie Studio (MVES) - Hollywoods Newest Brand - Expands Market to China
Feb 15 / Investing Channel - Paid Partner Content
Why Gilead Sciences Stock Slumped Today
Feb 08 / MotleyFool.com - Paid Partner Content
Gilead Sciences (GILD) Value Trap
Feb 15 / Investing Channel - Paid Partner Content
Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints
Feb 08 / Zacks.com - Paid Partner Content
Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)
Feb 15 / Zacks.com - Paid Partner Content
Gilead Sciences Just Lost $9 Billion in Market Value -- Here's Why
Feb 08 / MotleyFool.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
Feb 15 / Zacks.com - Paid Partner Content
Gilead Sciences Just Shocked Investors, And It Wasn't Good
Feb 08 / MotleyFool.com - Paid Partner Content
4 Stocks to Buy Near 52-Week Lows
Feb 15 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigat...
Feb 08 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Present...
Feb 15 / Zacks.com - Paid Partner Content
Healthcare Stocks: The Buying Opportunity of the Year?
Feb 07 / Zacks.com - Paid Partner Content
North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Communi...
Feb 14 / GuruFocus News - Paid Partner Content
Gilead Sciences Inc. Reports Q4 Earnings Decline and Worsening Outlook for 2017
Feb 07 / MotleyFool.com - Paid Partner Content
Gilead (GILD) Announces Data on Combination Therapy for HIV
Feb 14 / Zacks.com - Paid Partner Content
Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance
Feb 07 / Zacks.com - Paid Partner Content
3 Stocks We're Watching in the First Quarter
Feb 14 / MotleyFool.com - Paid Partner Content
3 Attractive Income Stocks Whose Dividends Could Double
Feb 07 / MotleyFool.com - Paid Partner Content